SG11201807783UA - Mutant bordetella strains and methods for use - Google Patents

Mutant bordetella strains and methods for use

Info

Publication number
SG11201807783UA
SG11201807783UA SG11201807783UA SG11201807783UA SG11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA SG 11201807783U A SG11201807783U A SG 11201807783UA
Authority
SG
Singapore
Prior art keywords
lille
international
subject
institut
calmette
Prior art date
Application number
SG11201807783UA
Other languages
English (en)
Inventor
Luis Solans
Camille Locht
Anne Tsicopoulos
Yahia Sendid Saliha Ait
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of SG11201807783UA publication Critical patent/SG11201807783UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201807783UA 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use SG11201807783UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (fr) 2016-03-29 2017-03-29 Souches mutantes de bordetella et procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201807783UA true SG11201807783UA (en) 2018-10-30

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807783UA SG11201807783UA (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Country Status (8)

Country Link
US (4) US10682377B2 (fr)
EP (1) EP3436034A1 (fr)
JP (1) JP6993984B2 (fr)
CN (2) CN114767718A (fr)
AU (2) AU2017242541B2 (fr)
CA (1) CA3018126A1 (fr)
SG (1) SG11201807783UA (fr)
WO (1) WO2017167834A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007224734C1 (en) * 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
AU2010243708C1 (en) 2009-04-28 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
CN114767718A (zh) * 2016-03-29 2022-07-22 里尔巴斯德研究所 突变型博德特氏菌属菌株及其使用方法
SG11202003333WA (en) * 2017-10-18 2020-05-28 Pasteur Institut Bordetella strains expressing serotype 3 fimbriae
EP4247397A1 (fr) 2020-11-17 2023-09-27 Iliad Biotechnologies, LLC Traitement et prévention de neuropathologie associée à des maladies neurodégénératives
WO2024018061A1 (fr) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Utilisation de souches de bordetella pour le traitement de la bronchopneumopathie chronique obstructive

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
AU2004229527B2 (en) 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
AU2007224734C1 (en) 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
JP2010508860A (ja) 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
EP2134359A4 (fr) 2007-02-23 2010-06-16 Penn State Res Found Utilisation d'un mutant de bordetella non virulent comme vecteur de vaccin vivant
EP2170921A4 (fr) 2007-06-18 2012-08-08 Hemispherx Biopharma Inc Intervention précoce d'activateurs immunitaires dans les infections virales
AU2010243708C1 (en) 2009-04-28 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
EP2442826B1 (fr) 2009-06-15 2015-07-08 National University of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
WO2013066272A1 (fr) * 2011-11-02 2013-05-10 National University Of Singapore Effet d'une souche atténuée de bordetella sur une maladie allergique
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (fr) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelles souches de bordetella de recombinaison
CN114767718A (zh) * 2016-03-29 2022-07-22 里尔巴斯德研究所 突变型博德特氏菌属菌株及其使用方法

Also Published As

Publication number Publication date
JP6993984B2 (ja) 2022-02-03
CN114767718A (zh) 2022-07-22
CA3018126A1 (fr) 2017-10-05
US10682377B2 (en) 2020-06-16
EP3436034A1 (fr) 2019-02-06
US20200323901A1 (en) 2020-10-15
JP2019513722A (ja) 2019-05-30
WO2017167834A1 (fr) 2017-10-05
US11065276B2 (en) 2021-07-20
US20170283890A1 (en) 2017-10-05
CN109069535B (zh) 2022-03-18
AU2017242541A1 (en) 2018-10-11
CN109069535A (zh) 2018-12-21
US20230381224A1 (en) 2023-11-30
AU2017242541B2 (en) 2022-06-30
US20210290667A1 (en) 2021-09-23
AU2022221438A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
SG11201807783UA (en) Mutant bordetella strains and methods for use
SG11201804934PA (en) Novel Compounds
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201805835WA (en) Modified oncolytic virus
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201805072PA (en) Nicotine powder delivery system
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201811250TA (en) Nicotine inhaler system
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201900238UA (en) Compounds and methods for modulation of smn2